ARN-0953

N/A

Report date: 2025/01/26 16:49:17
NME

Base Information

Drug NameARN-0953
Drug Alias NameMELK and FLT3 inhibitor (Arrien pharmaceuticals)ARN-0953
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase receptor FLT3 inhibitorsMaternal embryonic leucine zipper kinase inhibitors
TargetsMaternal embryonic leucine zipper kinaseTyrosine-protein kinase receptor FLT3
Therapy Area/IndicationsLung NeoplasmsTriple Negative Breast NeoplasmsGlioblastoma +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesArrien Pharmaceuticals Llc
China Registration ClassN/A

Develop Information

Active CompaniesArrien Pharmaceuticals Llc
Inactive CompaniesN/A
Active IndicationsLung NeoplasmsTriple Negative Breast NeoplasmsGlioblastoma +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A